Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Teva Pharmaceuticals USA Inc. has 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 7 pending office actions are being reviewed by 7 distinct examiners, showing a one-to-one ratio of actions to examiners. The prosecution is organized within 4 distinct art units, which provides some concentration of the technical subject matter being examined.
The busiest examiner, DAVIS, BRIAN J, is responsible for 1 busiest examiner pending action, mirroring the distribution seen across the rest of the 7 pending office actions. With 7 distinct examiners involved, practitioners must prepare for 7 different sets of examiner interviews and response styles. The 4 distinct art units represent the primary organizational hurdles for the 7 pending office actions, and understanding the specific nuances of these 4 distinct art units is essential. The lack of examiner overlap across the 7 pending office actions means that each case requires a bespoke prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 2 (29%) |
| Double-patenting only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, BRIAN J | 1 | 84.8% | -4.0% |
| RAO, SAVITHA M | 1 | 60.7% | +30.2% |
| LEE, ANDREW P | 1 | 48.3% | +23.1% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
| LIU, TRACY | 1 | 54.5% | +27.3% |
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
| MACH, ANDRE | 1 | 44.9% | +51.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18919039 | NOVEL PHARMACEUTICAL FORMULATIONS | DAVIS, BRIAN J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246582 | GASTRO RETENTIVE DOSAGE FORMS COMPRISING DEUTETRABENAZINE | MERCIER, MELISSA S | 28d |
| 18769264 | BENZOQUINOLONE INHIBITORS OF VMAT2 | RAO, SAVITHA M | — |
| 18677401 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | LEE, ANDREW P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18402393 | Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2 | LIU, TRACY | 42d overdue |
| 18245565 | MULTIPARTICULATE DOSAGE FORMS COMPRISING DEUTETRABENAZINE | MACH, ANDRE | 19d overdue |
| 18769264 | BENZOQUINOLONE INHIBITORS OF VMAT2 | RAO, SAVITHA M | — |
| 18677401 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | LEE, ANDREW P | — |
| Art Unit | Apps |
|---|---|
| 1614 | 2 |
| 1615 | 2 |
| 1691 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18919039 | NOVEL PHARMACEUTICAL FORMULATIONS | DAVIS, BRIAN J | 1614 | §102DP | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18769264 | BENZOQUINOLONE INHIBITORS OF VMAT2 | RAO, SAVITHA M | — | §102§103§112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18677401 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | LEE, ANDREW P | 1691 | §101§112DP | Non-Final OA | — | Pending | May 29, 2024 |
| 18692074 | MULTIPARTICULATE DOSAGE FORMS COMPRISING DEUTETRABENAZINE | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18402393 | Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2 | LIU, TRACY | 1614 | DP | Final Rejection | 42d overdue | Pending | Jan 02, 2024 |
| 18246582 | GASTRO RETENTIVE DOSAGE FORMS COMPRISING DEUTETRABENAZINE | MERCIER, MELISSA S | 1615 | §102§103 | Final Rejection | 28d | Pending | Mar 24, 2023 |
| 18245565 | MULTIPARTICULATE DOSAGE FORMS COMPRISING DEUTETRABENAZINE | MACH, ANDRE | 1615 | §103 | Final Rejection | 19d overdue | Pending | Mar 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial